Breye Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Breye Therapeutics - overview
Location
Copenhagen, -, Denmark
Primary Industry
Biotechnology
About
Based in Copenhagen, Denmark, and founded in 2019, Breye Therapeutics ApS operates as a biopharmaceutical company that develops and provides ophthalmology therapies for retinal vascular diseases. The company was founded by its CEO, Ulrik Mouritzen. In November 2022, Breye Therapeutics raised EUR 4 million in seed funding co-led by investors Novo Holdings and Sound Bioventures, with participation from other investors BioInnovation Institute, Dansk Vækstkapital, and Innovationsfonden. The company focuses on providing therapeutic options for people who are at risk of vision loss or blindness due to retinal vascular disorders.
They specialize in producing tiny compounds that can be taken orally, with a focus on diabetic retinopathy (DR) and age-related macular degeneration (AMD).
Current Investors
Danske Private Equity, Novo Holdings, Innovationsfonden
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Optometrists & Opticians Products and Services
Website
www.breyetx.com
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.